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The gabapentinoid pregabalin is a rapid-acting anxiolytic and analgesic, 
possibly suitable in supervised opioid detoxification. However, clinicians have 
been cautious using it because of its unknown addictive risk and rising 
number of mortalities after pregabalin self-medication in opioid abusers. Here, 
we studied interactions of pregabalin and morphine on reward functions of the 
dopamine (DA) system in mice and the efficacy of pregabalin on withdrawal in 
opioid addicts. After the treatment of mice with pregabalin and morphine, we 
used electrophysiology to study neuroplasticity in midbrain slices, self-
administration and conditioned place preference tests to investigate the 
rewarding potential of pregabalin, and naloxone-precipitated morphine 
withdrawal to evaluate opioid withdrawal symptoms. Further, we ran a pilot 
single-blind, randomized, controlled trial (34 heroin addicts) to evaluate the 
efficacy and safety of pregabalin in the treatment of opioid withdrawal 
syndrome. Pregabalin alone did not induce glutamate receptor neuroplasticity 
of DA neurons in the ventral tegmental area (VTA), but pretreatment with 
pregabalin suppressed morphine-induced neuroplasticity, hyperlocomotion 
and morphine self-administration. Pregabalin administration after chronic 
morphine exposure failed to induce any rewarding effects. Instead, pregabalin 
suppressed withdrawal symptoms in both morphine-treated mice and opioid 
addicts, and was well tolerated. Intriguingly, pregabalin administration after a 
low dose of morphine strongly facilitated VTA neuroplasticity and led to 
increased conditioned place preference. Pregabalin appears to have the 
efficacy to counteract both reinforcing and withdrawal effects of opioids, but it 
also has a potentiating effect when given to mice with existing opioid levels.  
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Opioid dependence is a complex chronic disorder that affects numerous brain 
systems leading to a range of physical, learning, and behavioral effects (Koob 
and Volkow, 2016). Currently approved treatment protocols for opioid 
dependence include several stages (supervised withdrawal, followed by 
opioid antagonist treatment) and require polydrug therapy to suppress various 
withdrawal symptoms in the beginning of treatment (Sigmon et al., 2012). 
Even with the most advanced and intensive treatment, patients show poor 
compliance and experience severe adverse effects (Collins et al., 2005). New 
treatment strategies which reduce the severity of withdrawal and make the 
initiation of antagonist therapy shorter, less symptomatic, and easier to 
manage are greatly needed. 
Pregabalin (S-(+)-3-isobutyl g-aminobutyric acid), a gabapentinoid 
compound, has become the first-line treatment of neuropathic pain and is 
recommended as a potential first-line treatment for generalized anxiety 
disorder, being one of the most effective and safe drugs to date (Bandelow et 
al., 2008; Kremer et al., 2016). Importantly, pregabalin shows a rapid onset of 
action, has no active metabolites and minimal hepatic metabolism: a profile 
that makes it easy to use in clinical practice (Buoli et al., 2017). Indeed, its 
simultaneous analgesic and anxiolytic effects and its pharmacokinetic profile 
could also be beneficial for the treatment of opioid withdrawal syndrome 
(Sigmon et al., 2012). However, only a few studies have investigated the 
efficiency of gabapentinoids in opioid withdrawal treatment (Freynhagen et al., 
2016).  
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Although pregabalin is structurally related to g-aminobutyric acid, 
GABA, it does not act on GABAA or GABAB receptors, nor on GABA reuptake 
transporters (Lanneau et al., 2002; Li et al., 2011). Instead, it has a selectively 
high affinity to an auxiliary a2d subunit of presynaptic voltage-gated Ca2+ 
channels (Taylor et al., 2007). Through this interaction with the a2d subunit, 
pregabalin attenuates Ca2+ influx into cells, and thereby suppresses Ca2+-
dependent presynaptic release of various neurotransmitters, including 
glutamate, noradrenaline and substance P (Dooley et al., 2000; Field et al., 
2006; Taylor et al., 2007). Furthermore, another gabapentinoid, gabapentin, 
suppresses synaptogenesis and the trafficking of Ca2+ channels to the cell 
surface, in line with the interference of functions of the a2d subunits (Bauer et 
al., 2009; Eroglu et al., 2009). Autoradiography has shown high-affinity 
binding in the cortex, olfactory bulb, hypothalamus, amygdala, and 
hippocampus, and to a lesser extent in the ventral tegmental area (VTA) (Bian 
et al., 2006; Taylor et al., 2007). Functional magnetic resonance imaging has 
detected that pregabalin influences the activation of the insula and locus 
coeruleus, brain regions which play important roles in anxiety and opioid 
withdrawal (Aupperle et al., 2011; Koob, 2008; Takeuchi et al., 2007).  
Importantly, although no systematic assessment of pregabalin’s effects 
on reward mechanisms exists (Andrews et al., 2001; Chiappini and Schifano, 
2016), recent animal studies and human case reports have suggested that 
pregabalin might be beneficial in treating opioid withdrawal. In fact, pregabalin 
suppressed naloxone-precipitated opioid withdrawal signs in a dose-
dependent manner in morphine-treated rats without preventing analgesic 
morphine tolerance (Hasanein and Shakeri, 2014; Jokinen et al., 2015). A 
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case study reported that pregabalin ameliorated withdrawal signs within a 
week in an opiate user with a history of multiple unsuccessful detoxifications 
(Kammerer et al., 2012). It should also be noted that, recently, pregabalin has 
frequently been used by opioid abusers seeking self-detoxification (Wilens et 
al., 2015).  
Nonetheless, clinicians are concerned about treating drug abusers with 
pregabalin because of its potential addictive risk. Pregabalin has been 
reported to produce a euphoric state and misuse in some patients with a 
history of opioid use (Grosshans et al., 2013), and, moreover, the number of 
deaths attributed to the combination of pregabalin and opioids has recently 
risen (Hakkinen et al., 2014). This may be due to the fact that pregabalin at 
unknown instances produces benzodiazepine-like effects and acts as an 
opioid booster (Ojanpera et al., 2016; Pesonen et al., 2011). Importantly, in 
rats, co-administration of morphine and pregabalin did not produce changes in 
brain concentrations of morphine, its major metabolites or pregabalin (Jokinen 
et al., 2015), indicating that there are no pharmacokinetic interactions 
between pregabalin and opioids. The conditions and underlying mechanisms 
of the pharmacodynamic interactions of pregabalin and opioids in opioid users 
and in mouse addiction models have not been investigated.  
We report here a detailed analysis of the effects of pregabalin on the 
dopamine reward system in acute experiments and after long-term morphine 
exposure in mice. We further model the conditions resulting in an increase of 
reinforcing properties of pregabalin. We also report the results of a pilot 
randomized single-blind trial to assess the efficacy and safety of pregabalin 
treatment of opiate withdrawal. 
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Materials and methods 
Preclinical studies 
Animals and in vivo manipulations 
We used juvenile (22-30 days old) male and female transgenic TH-EGFP 
mice (Gong et al., 2003) for electrophysiology, and adult (8-11 weeks old) 
male C57BL/6JCrl mice (Charles River Germany, Sulzfield, Germany) for 
behavioral studies. All drug injections (s.c., i.v., or i.p.) and behavioral tests 
were performed between 08:00 and 19:00, with lights on between 6:00 and 
18:00. All animal work was conducted according to relevant national and 
international guidelines. Animal experiments were authorized by the national 
Animal Experiment Board in Finland (Eläinkoelautakunta, ELLA). 
 
Electrophysiological experiments 
The TH-EGFP mice were decapitated 24 h after the treatment, between 9:00 
and 13:00. Patch-clamp recordings from VTA DA neurons ex vivo from 
horizontal midbrain slices were performed essentially as previously described 
(Vashchinkina et al., 2012). Evoked excitatory postsynaptic currents (EPSCs) 
were recorded in the presence and absence of an N-methyl-D-aspartate 
receptor (NMDAR) blocker, D-(-)-2-amino-5-phosphonopentanoic acid (AP5, 
50 μM), to obtain a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
receptor (AMPAR) and AMPAR + NMDAR -mediated currents, respectively. 
The AMPA/NMDA ratio was calculated by dividing the peak amplitude of the 
AMPA receptor current with that of the NMDA receptor current, averaged from 
18 EPSCs. The weighted decay time constant (tau, tW) of the NMDAR 
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EPSCs at +40 mV was calculated by fitting a double exponential function to 
each average EPSC and using the following formula: tW = [(A1 ´ t1) + (A2 ´ 
t2)]/(A1 + A2), where A1 and A2 are the amplitudes and t1 and t2 are the 
decay time constants of the fast and slow components, respectively (Barth 
and Malenka, 2001). For additional information, see the Supplementary 
information.  
 
Behavioral experiments  
In vivo drug treatments with mice  
For acute experiments, mice were pretreated with pregabalin (50-200 mg/kg, 
i.p.) or its vehicle, and 30 min later they were treated with morphine (1-10 
mg/kg, s.c.), or vice versa (treatment protocols in Figures 2 and 5). For 
chronic experiments, mice were treated with escalating doses of morphine 
(s.c.) every 16 h over a period of 4 weeks. One week after the last morphine 
injection, the mice were tested for conditioned place preference (CPP) and 3 
weeks after the last morphine injection, for intravenous self-administration of 
pregabalin (treatment protocol in Figure 4). The morphine dose was increased 
as follows: 10-20 mg/kg on week 1, 20-30 mg/kg on week 2, 30-40 mg/kg on 
week 3 and 50-70 mg/kg on week 4. Each week, the dose of morphine was 
increased by 10 mg/kg, when the mice developed tolerance to the previous 
dose, assessed as a blunting of the morphine-induced hyperactivity in 
comparison to previous doses. Two independent batches of mice were tested.  
 
Spontaneous locomotor activity 
Mouse locomotor activity was analyzed by video-tracking software Ethovision 
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XT (Version 10.1, Noldus Information Technology, Wageningen, the 
Netherlands) for 90 min in 19 x 36 cm cages (Vashchinkina et al., 2012). 
Distances travelled during successive 15-min periods were calculated and 
compared between the treatments. 
 
Conditioned place preference  
The biased place conditioning paradigm consisted of 15-min pre-conditioning, 
30-min conditioning, and 15-min post-conditioning periods, as previously 
described (Vekovischeva et al., 2004). Conditioning training was performed 
over 4 days: morning conditioning with the vehicle and evening conditioning 
with the drugs. The difference (‘‘timeshift’’) in time spent on the initially non-
preferred material during pre-conditioning and post-conditioning tests was 
calculated as a measure of CPP. For additional information, see the 
Supplementary information. 
 
Intravenous drug self-administration 
The drug self-administration procedure, based on voluntary nose-poking 
activity of the mice, was carried out as previously described (Vashchinkina et 
al., 2012). Briefly, employing the yoked-control paradigm, each nose-poke 
resulted in a simultaneous infusion (1.7 μl; duration 1 s) of pregabalin (5 
mg/ml) or morphine (1 mg/ml) via the tail vein to both active and yoked-control 
mice. Mice were allowed to self-administer drugs for 20 min. As a measure of 
reinforcement, the R factor was calculated (Vashchinkina et al., 2012). For 
detailed information, see the Supplementary information. 
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Naloxone-precipitated morphine withdrawal  
Mice were treated with escalating daily doses of morphine (8-45 mg/kg, s.c.) 
for 5 days, with injections at 8:00 and 18:00 (Suzuki et al., 1996). Withdrawal 
symptoms were precipitated by injecting naloxone (3 mg/kg, s.c.) 2 h after the 
last administration of morphine on the morning of Day 5 (treatment protocol in 
Figure 3). Pretreatment with pregabalin (50 mg/kg) occurred 30 min prior to 
naloxone injections. After the naloxone precipitation, mice were immediately 
placed in an acrylic cylinder (30 cm high, 20 cm in diameter). The number of 
jumps, exploratory rears, and forepaw tremor behaviors were counted for 30 
min after the naloxone injection.  
 
Clinical study 
A six-day single-blind, randomized, controlled trial evaluated the efficacy of 
pregabalin in the detoxification of patients with opioid use disorder assigned to 
the inpatient withdrawal program. We randomly assigned 34 adult patients 
(details in Table1) diagnosed with heroin dependence (ICD-10) to either 600 
mg/day of pregabalin or 600 μg/day of clonidine (an a2 adrenoceptor agonist) 
using a random number generator method (Figure 1). Participants also 
received 30 mg of doxylamine (a sedative antihistamine) daily and other 
symptom-triggered symptomatic therapy (Table S1). The study was 
conducted at two sites in Russia and registered at ClinicalTrials.gov, 
NCT03017430. Results of the trial have been partially reported in a Russian 
language journal (Krupitsky et al., 2016). 
The primary outcome was completion of the withdrawal treatment 
program as defined by standard physician-rated and patient-rated quantitative 
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psychometric scales. The secondary outcomes were: amount of symptom-
triggered medications administered (NSAIDs), severity of withdrawal 
symptoms (efficacy), and number of reported adverse events using daily self-




For mouse studies, morphine hydrochloride powder and pregabalin capsules 
(Lyrica, Pfizer, New York City, NY, USA) were purchased from the University 
Pharmacy (Helsinki, Finland). The morphine was dissolved in saline and 
injected s.c. in a volume of 10 ml/kg. The morphine concentrations are given 
as free base per unit of volume. Pregabalin was dissolved in 0.5% 
methylcellulose in physiological saline and administered i.p. in a volume of 10 
ml/kg. For i.v. administration, pregabalin (Tocris Bioscience, Bristol, UK) was 
dissolved in saline.  
For the clinical trial: pregabalin capsules (Lyrica, Pfizer, New York City, 
NY, USA), clonidine tablets (Clopheline, Organica, Novokuznetsk, Russia), 
doxylamine tablets (Donormyl, UPSA SAS, Agen, France), an NSAID, 
ketorolac (Ketanove, Ranbaxy, Dewas, India), 
bromdihydrochlorphenylbenzodiazepine (Phenazepam, Valenta Pharm, 
Schyolkovo, Russia), metoclopramide (Cerucal, Teva Pharmaceutical 
Industries, Godollo, Hungary), loperamide (Imodium, Johnson & Johnson, 
Catalent UK Swindon Zydis Ltd., Swindon, UK), naphazoline (Naphthyzin, 
Sintez, Kurgan, Russia, or Sanorin, Teva Pharmaceutical Industries, Opava-




The results are presented as means ± SEM. Data were statistically analyzed 
using the IBM SPSS Statistics 21 software (IBM, Armonk, New York, NY, 
USA). Preclinical studies were analyzed using one-way or two-way ANOVAs 
followed by a Bonferroni test or unpaired Student’s t-tests (p < 0.05). The 
clinical study was analyzed using the intention-to-treat approach. The primary 
outcome was analyzed using Mantel-Cox log rank and Kaplan-Meier survival 
curves, and secondary outcomes either by Fisher's exact test for categorical 




Acute pregabalin inhibited morphine-induced hyperlocomotion, self-
administration, VTA DA-neuron neuroplasticity, and morphine 
withdrawal symptoms  
 
Pretreatment with pregabalin dose-dependently attenuated morphine-induced 
hyperlocomotion (Figure 2A; pretreatment effect: F3,57 = 5.7, p < 0.01). 
Pregabalin alone at doses of 50-200 mg/kg (i.p.) did not alter locomotor 
activity in mice, compared to the vehicle (F3,22 = 0.3, p = 0.8).  
We then tested whether pregabalin altered the reinforcing properties of 
morphine. Using acute i.v. self-administration, we found that the nose-poking 
for morphine and the morphine intake during the session, at an infused 
concentration known to be self-administered by mice (Kuzmin et al., 1997), 
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were significantly attenuated by pretreatment with pregabalin (50 mg/kg, i.p.) 
(Figure 2B-C). Pregabalin infusion did not sustain any enhanced nose-poking 
behavior. 
We also determined whether the pretreatment with pregabalin affects 
morphine-induced neuroplasticity in VTA DA neurons (Ungless et al., 2001; 
Vashchinkina et al., 2012). The morphine-induced increase in the 
AMPA/NMDA ratio in the VTA DA neurons 24 h after the single morphine 
dose (10 mg/kg, s.c.) was suppressed by pregabalin (50 mg/kg, i.p.) given 30 
min before the morphine (Figure 2D; pretreatment effect: F3,27 = 5.4, p ˂ 0.01). 
The weighted decay time constants (tW) of the NMDAR EPSCs were similar 
for all groups (treatment factor: F3,36 = 2.3, p = 0.09; tW given as mean ± 
SEM: vehicle, 58 ± 6 ms; morphine (10 mg/kg), 74 ± 4 ms; pregabalin (50 
mg/kg), 58 ± 6 ms; pregabalin (50 mg/kg) + morphine (10 mg/kg), 72 ± 6 ms). 
We next asked whether a single injection of pregabalin is sufficient to 
suppress morphine withdrawal in mice. To address this question, we injected 
pregabalin (50 mg/kg) or vehicle 30 min prior to precipitation of withdrawal 
symptoms with naloxone (3 mg/kg) in subchronically morphine-treated mice 
(Figure 3). Pregabalin pretreatment significantly attenuated withdrawal signs, 
defined as jumps and tremor episodes, compared to vehicle pretreatment 
(Figure 3, t-test, p ˂ 0.05). The number of rears remained similar in both 
pretreatment groups.  
Together, these results suggest that pregabalin alone is insufficient to 
induce rewarding behavior, but that, when used as a pretreatment, it 
effectively attenuates voluntary intake of morphine, morphine-induced 
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neuroplasticity in the VTA, and withdrawal symptoms from subchronic 
morphine treatment in mice.  
 
Past long-term morphine exposure failed to alter the rewarding effects 
of pregabalin 
 
Taking into account several reports regarding the misuse of pregabalin in 
subjects with an opiate history (Grosshans et al., 2013), we tested whether 
long-term morphine exposure modifies the rewarding properties of pregabalin. 
To address this, mice were treated with escalating doses of morphine for four 
weeks, one week thereafter they were subjected to place conditioning with 
pregabalin, and again one week later the mice were given access to acute i.v. 
self-administration of pregabalin (Figure 4A).  
Expectedly, morphine-exposed mice lost weight (Figure 4A, t-test, p < 
0.01), and they showed lower locomotor activity during the morning vehicle-
conditioning sessions as compared to the morphine-naïve group (Figure 4C, 
morphine exposure ´ pregabalin dose interaction: F1,39 = 4.0, p = 0.05). 
However, morphine-exposed mice showed significant sedation after the 
higher pregabalin dose (100 mg/kg) during pregabalin-conditioning sessions 
(Figure 4C, morphine exposure ´ pregabalin dose interaction: F1,39 = 4.9, p = 
0.03), but the timeshifts during preference testing remained similar between 
the groups (Figure 4B-C, morphine exposure effect: F1,39 = 0.01, p > 0.05).  
One week after the CPP test, these mice were tested regarding 
voluntary i.v. pregabalin self-administration. Noteworthy, morphine-exposed 
mice had similar nose-poking activity as the control mice (Figure 4D, t-test, p 
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> 0.05). During 20-min sessions, both groups self-administered the same 
amount of pregabalin (Figure 4E-F, t-test, p > 0.05). In conclusion, we found 
that both place conditioning and pregabalin self-administration were not 
affected by morphine exposure history. The morphine-experienced mice were 
slightly more sensitive to sedation by pregabalin than the control mice, but no 
clear rewarding effects of pregabalin were detected in either group.  
 
Low doses of morphine followed by pregabalin provoked plasticity in 
VTA DA neurons and place preference 
 
The fact that pregabalin acts on “overexcited” synapses (Dooley et al., 2000; 
Fehrenbacher et al., 2003) led us to hypothesize that administration of 
pregabalin after morphine may more robustly suppress the effects of 
morphine than when given in the reverse order. To test this idea, mice were 
first pretreated with morphine (1-10 mg/kg, s.c.), and then 30 min later they 
were treated with pregabalin (50 mg/kg, i.p.). Afterward, we studied the drug-
induced neuroplasticity in VTA DA neurons and place conditioning. 
Consistent with previous reports (Saal et al., 2003), morphine dose-
dependently increased the AMPA/NMDA ratio in VTA DA neurons at 24 h 
after treatments (Figure 5A; morphine effect: F3,30 = 8.9, p < 0.001). To our 
surprise, the additional post-treatment with pregabalin (50 mg/kg) robustly 
potentiated the effect from the low doses of morphine (1-3 mg/kg), seen as an 
increase in the AMPA/NMDA ratio (Figure 5A; pregabalin effect: F1,40 = 8.9, p 
< 0.001). This is to be compared with the attenuation of morphine-induced 
neuroplasticity by pretreatment with pregabalin (see Figure 2D). 
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We then examined whether the combination of low doses of morphine 
(1-3 mg/kg) with pregabalin post-treatment (50 mg/kg) also altered the 
reinforcing properties of morphine by studying the development of CPP 
(Figure 5B-E). In line with the neuroplasticity results, mice treated with 
morphine (1 mg/kg) followed by pregabalin post-treatment before each 
conditioning session showed significant positive timeshifts (preference) as 
compared to those post-treated with the vehicle (Figure 5B; treatment effect: 
F3,35 = 8.5, p < 0.001). Furthermore, the expression of place preference was 
significantly different (p < 0.05) from the group that had the opposite treatment 
regime: treatment with pregabalin and post-treatment with morphine (1 mg/kg) 
before conditioning failed to induce place preference (Figure 5B). During the 
conditioning sessions, only the morphine-pregabalin group showed some 
hyperlocomotion as compared to all other groups (Figure 5D; treatment effect: 
F3,28 = 16.7, p < 0.01).  
A small increase of the morphine dose to 3 mg/kg, however, eliminated 
the difference in the timeshifts induced by pregabalin post-treatment: 
morphine alone, morphine-pregabalin and pregabalin-morphine regimes all 
induced identical timeshifts (Figure 5C; treatment effect: F3,35 = 8.5, p < 
0.001). This dose of morphine also strongly induced locomotor activity during 
conditioning sessions as compared to the lower dose (Figure 5C-E; treatment 
effect: F3,28 = 33.5, p < 0.001).  
 
Pregabalin suppressed opioid withdrawal in human subjects  
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To translate part of the preclinical data presented above to clinical conditions, 
we ran a pilot study of the efficacy and safety of pregabalin in the treatment of 
opioid withdrawal syndrome (Figure 1). The groups did not differ in their 
clinical characteristics (Table 1). Among the pregabalin group, 15 of 19 
patients (79%) completed the 6-day treatment, whereas only 7 of 15 patients 
(47%) of the clonidine group did (Fisher’s exact test, p = 0.05). Kaplan-Meier 
survival analysis further confirmed the better patient retention in the 
pregabalin group (Figure 6A; Log Rank (Mantel-Cox) criterion, p = 0.001). 
Overall changes of opioid withdrawal severity remained similar in both 
treatment groups, probably due to the symptom-triggered study design 
(Figure 6H-J; treatment effect: F1,5 < 0.9, p ˃ 0.05).  
The pregabalin group reported better well-being (Figure 6B; treatment 
effect: F1,5 = 4.8, p = 0.03) and lower scores for opioid cravings (Figure 6E; 
treatment effect: F1,5 = 3.7, p = 0.05), depression (Figure 6F; treatment effect: 
F1,5 = 5.4, p = 0.02) and anxiety (Figure 6G; treatment effect: F1,5 = 3.7, p = 
0.057). Furthermore, the average dose of symptom-triggered ketorolac in the 
pregabalin group was almost half of that in the clonidine group (Figure 6D; t-
test, p = 0.04). While the total rate of adverse events was similar in both 
groups (about 73% of patients), the pregabalin group reported less fatigue, 
lack of energy and asthenia (16% vs. 47%; Fisher’s exact test, p < 0.05). 
Taken together, reduced cravings, fatigue and analgesic requirements in the 
pregabalin-treated patients indicate improved efficacy and tolerability of the 
pregabalin-based approach in the treatment of opioid withdrawal compared to 
the clonidine-based one, resulting in a higher rate of completion of the 
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detoxification program. No serious or severe adverse events of pregabalin 
were noted in this study. 
 
Discussion 
The question of whether pregabalin is a safe drug, especially for drug 
abusers, is still debated. Case reports that advocate or criticize the use of 
pregabalin in opioid abusers provide little basis for scientific generalization. In 
the present study, we examined the addictive profile of pregabalin in mice, the 
effects of pregabalin and morphine combination in different addiction-related 
settings, and ran the first clinical trial on the efficacy and safety of pregabalin 
in 34 opiate abusers. The key issues that are necessary to consider when co-
administering pregabalin and morphine appear to be the order and time of 
drug administration.  
To our knowledge, there are no published data on possible 
interspecies differences in pregabalin-induced psychoactive/toxicity effects. A 
recent translational study (Lyndon et al., 2017) showed that, in mice, co-
administration of pregabalin and morphine resulted in significantly greater 
respiratory depression than administrations of morphine or pregabalin 
separately. In the same study, heroin users reported that the combination of 
heroin and pregabalin often reinforced the effects of heroin, increasing the risk 
for an overdose. Another study in rats showed that pregabalin potentiated the 
antinociceptive and sedative effects of oxycodone and morphine without 
alterations in brain concentrations of opioids or pregabalin (Jokinen et al., 
2015). Taken together, these data suggest that results from preclinical models 
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can translate to human conditions in the study of the psychoactive/toxicity 
effects of pregabalin and morphine. 
We observed anti-addiction, protective efficacy of pregabalin on the 
development of morphine-induced neuroadaptations in VTA DA neurons, 
psychomotor activation (hyperlocomotion) and self-administration, when mice 
received pregabalin prior to morphine. Generally, that is in line with the effects 
of benzodiazepine pretreatment on the effects of morphine (Panhelainen et 
al., 2011), except for the fact that the doses of pregabalin used here did not 
induce sedation or glutamatergic synaptic plasticity, unlike the 
benzodiazepines (Heikkinen et al., 2009; Tan et al., 2011). The plasticity that 
morphine induces in VTA DA neurons is known to be dependent on NMDARs 
(Brown et al., 2010). Recent studies have demonstrated that pregabalin 
attenuates the levels of D-serine, an endogenous co-agonist of NMDARs, 
which leads to a shortening of the decay of NMDAR currents (Kato et al., 
2016; Singh et al., 2013). This down-regulation of D-serine levels would 
suppress morphine-induced plasticity in VTA DA neurons. In fact, earlier 
reports have shown that the selective glycine/D-serine-site antagonist of the 
NMDAR, L-701,324, significantly suppresses morphine-induced CPP 
(Kotlinska and Biala, 1999). However, detailed post hoc analysis of the 
kinetics of the NMDAR-mediated EPSCs did not reveal significant differences 
in VTA DA neurons between control and pregabalin-pretreated groups; thus, 
the mechanism of the attenuation of morphine-induced neuroplasticity in VTA 
DA neurons remains unknown.  
An important and unexpected finding was that pregabalin acted as an 
opioid booster when it was administered after an acute low dose of morphine 
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in mice. This treatment schedule potentiated morphine-induced neuroplasticity 
ex vivo in VTA DA neurons and reward in the CPP test. Noteworthy, opioid-
antagonist pretreatment did not alter pregabalin effects on the animals’ 
respiration (Lyndon et al., 2017), indicating that pregabalin action is not 
associated with a pregabalin-induced release of endogenous opioids or direct 
activation of opioid receptors.  
Gabapentinoids, especially pregabalin, is often used clinically in 
neuropathic pain (Finnerup et al., 2015), with the idea that they might prevent 
the spinal neuroplasticity formation associated with neuropathy (Verma et al., 
2014). Indeed, there are multiple effects of gabapentinoids, although their 
primary target of action and high-affinity binding site is on the a2d auxiliary 
subunit of Ca2+ channels (Taylor et al., 2007), which results in reduced 
trafficking of calcium channels to plasma membranes (Bauer et al., 2010). 
Other effects of gabapentinoids include the reduction of presynaptic 
neurotransmitter release (Taylor et al., 2007), the calming effect on hyper-
excited glutamatergic synapses (Dooley et al., 2000; Fehrenbacher et al., 
2003) and the suppression of new synapse formation via the thrombospondin-
dependent mechanism (Eroglu et al., 2009). All of which may have 
contributed to the anti-addiction efficacy we detected in opioid self-
administration and the mesolimbic neuroplasticity and attenuation of opioid 
withdrawal symptoms. Since we also observed pro-addictive responses to 
opioids by post-treatment with pregabalin, the involvement of several 
neurotransmitters, rather than a simple summation of drug effects (e.g., 
disinhibition), needs to be considered in future studies.  
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Most importantly, pregabalin treatment strongly attenuated opioid 
withdrawal symptoms in mice and retained the heroin addicts in detoxification 
treatment better than the treatment with clonidine, the positive control drug. 
Indeed, in our present pilot clinical trial, pregabalin treatment effectively 
suppressed withdrawal symptoms during the 6-day treatment without any 
serious adverse events. Furthermore, pregabalin-treated patients required 
less of the NSAID ketorolac during the trial. This decrease in the amount of 
analgesic drug requirement remains an important indicator of the efficiency of 
the pregabalin therapy, because it suggests a clear reduction in pain-related 
symptoms during opiate withdrawal when treated with pregabalin. Of note, 
there was a significant reduction by the pregabalin therapy over the clonidine 
control therapy on the scores for craving, anxiety and depression, and an 
increase in general well-being. Thus, these results are in line with recent case 
reports on pregabalin (Freynhagen et al., 2016) and a trial with gabapentin as 
an add-on to methadone-assisted detoxification (Salehi et al., 2011). 
Despite recent reports of a rapid rise in the misuse of pregabalin, it is 
necessary to separate the cases of abuse of and dependence on pregabalin 
from, first, pseudoaddiction cases occurring because of inadequate pain 
treatment rather than drug dependence (Weissman and Haddox, 1989), and, 
second, from “off-label” cases of pregabalin use as a self-treatment of opiate 
withdrawal symptoms (Wilens et al., 2015). According to a recent systematic 
review, “pregabalin misuse or abuse may be limited to the population of 
individuals already predisposed to substance abuse, rather than this issue 
widely occurring in the general population” (Freynhagen et al., 2016). Our 
clinical and preclinical results, which show the lack of rewarding effects of 
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pregabalin even after one month of chronic morphine exposure in mice, 
further narrow the size of the possible at-risk group.   
In conclusion, our study provides additional evidence for the efficacy 
and safety of pregabalin-based treatment in opioid withdrawal in a controlled 
hospital setting. However, the risk of pro-addictive effects from pregabalin, 
when added to the ambient low-dose opioid effect, should promote measures 
preventing its use as self-medication in opioid users. 
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Table 1. Demographics of participants and clinical characteristics of the 
pregabalin and clonidine groups 
Measure Pregabalin (n=19) Clonidine (n=15) 
Gender (% male) 79% 40% # 
Age in years (mean ± SEM) 31.8 ± 1.1 28.7 ± 1.1 
Unemployment rate (%) 58% 100% 
Lifetime use of opioids in years (mean ± SEM) 9.9 ± 1.4 7.9 ± 1.3 
Time since the last heroin administration in hours (mean ± SEM) 11.9 ± 1.3 12.5 ± 2.8 
Tolerance to heroin in grams (mean ± SEM) 3.5 ± 0.9 2.2 ± 0.4 
Number of completed detoxifications (mean ± SEM) 3.8 ± 1.3 3.2 ± 0.8 
Number of initiated detoxifications in the past (mean ± SEM) 4.2 ± 0.9 2.8 ± 0.9 





Summary of participant flow during the intention-to-treat study.  
 
Figure 2. 
Effects of pregabalin pretreatment on morphine-induced hyperlocomotion, i.v. 
self-administration of morphine, and neuroplasticity in VTA DA neurons at 24 
h after morphine administration. (A) Treatment protocol is on the top. 
Cumulative locomotor activity for 90 min after injections of the vehicle (Veh) 
and drugs in adult C57BL/6J mice. Morphine (10 mg/kg, n = 13; M10) induced 
clear hyperlocomotion (* p < 0.05, compared to vehicle). Non-sedative doses 
of pregabalin (50-200 mg/kg, i.p., n = 6-16; P50, P100 and P200) 
administered 30 min prior to morphine, dose-dependently attenuated the 
hyperlocomotion (pretreatment effect: F3,57 = 5.7, p < 0.01, Bonferroni # p < 
0.05, ## p < 0.01, ### p < 0.001 as compared to morphine). (B) Drug-naïve 
adult C57BL/6J mice were allowed to intravenously self-administer either 
pregabalin (5 mg/ml) or morphine (1 mg/ml) during 20-min sessions. A 
positive reinforcement factor indicates positive reinforcement. In contrast to 
pregabalin, morphine induced a significant increase in the reinforcement 
factor. Pretreatment with pregabalin (50 mg/kg, i.p.) suppressed morphine 
self-administration (treatment factor: F3,50 = 5.2, p < 0.01, Bonferroni * p < 0.05 
as compared to saline (Sal), # p < 0.05 as compared to morphine, n = 6-26 
pairs of mice). SA, self-administration. (C) Dose of morphine, which was self-
administered during the 20-min session (* p < 0.05, t-test). (D) Representative 
traces of AMPAR- and NMDAR-mediated currents (scale bar = 50 pA/50 ms, 
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left) and AMPA/NMDA  ratios in VTA DA neurons of midbrain slices obtained 
ex vivo 24 h after the drug injection in TH-EGFP mice (Bonferroni ** p < 0.01 
as compared to vehicle, n = 7-8 mice, right). Bars are means + SEMs. 
 
Figure 3.  
Effects of pregabalin treatment on naloxone-precipitated withdrawal 
symptoms in morphine-dependent mice. Top: treatment schedule of twice 
daily injections of morphine (8-45 mg/kg, s.c.), followed by naloxone (3 mg/kg, 
i.p.) on the final day of the experiment, 2 h after the last dose of morphine. 
Pregabalin (50 mg/kg, i.p.; P50) or vehicle (Veh) was administered 30 min 
before the naloxone. Bottom: effects of pregabalin pretreatment on naloxone-
precipitated jumps (A), tremor episodes (B) and rears (C) during the 30 min 
naloxone-precipitated withdrawal (n = 9 mice per group). Bars are means + 
SEMs. * p < 0.05, t-test. 
 
Figure 4. 
Effects of long-term morphine exposure on pregabalin-induced place 
conditioning in mice and i.v. self-administration of pregabalin. (A) Study 
design and scheme of the 4-week escalating-dose morphine treatment, with 
associated weight loss. Morphine was administered at 16 h intervals (10-70 
mg/kg, s.c.). One week after the last dose of morphine, the place conditioning 
paradigm was used (B, C) and, three weeks after, i.v. self-administration was 
used (D - F) to test for possible rewarding effects of pregabalin. (B) 
Expression of place conditioning to pregabalin (50 and 100 mg/kg, P50 and 
P100), given as timeshifts between post- and pre-conditioning times spent in 
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the drug-paired compartment of the apparatus in morphine-naïve (Mor_N, n = 
12) and morphine-exposed (Mor_E, n = 6-13) mice. The post-test was carried 
out 48 h after the last conditioning session. The timeshifts did not differ 
between groups (morphine exposure effect: F1,39 = 0.01, p = 0.9; pregabalin 
dose effect: F1,39 = 1.6, p = 0.2). (C) Locomotor activity during the four 30-min 
conditioning sessions after injections of the vehicle and pregabalin. Mor_E 
mice were less active than Mor_N mice in the vehicle (morphine exposure 
effect: F1,39 = 44.1, p ˂ 0.001; P50 group:  Mor_N vs. Mor_E * p < 0.01; P100 
group:  Mor_N vs. Mor_E # p < 0.01) and pregabalin (morphine exposure 
effect: F1,39 = 11.8, p ˂ 0.001; P100 group: Mor_N vs. Mor_E # p < 0.01) 
sessions. (D) Nose-poke activity during a pretest prior to i.v. self-
administration (SA) of pregabalin (5 mg/ml) was similar in Mor_N (n = 25) and 
Mor_E (n = 17) mice (t-test, p > 0.05). The reinforcement factor for pregabalin 
(E) and the dose of pregabalin voluntarily self-injected (F) during 20-min SA 
sessions were similar in Mor_N (n = 12 pairs) and Mor_E (n = 8) mice (t-test, 




Effects of low morphine doses before pregabalin administration on persistent 
neuroplasticity in VTA DA neurons and place conditioning. Treatment protocol 
for electrophysiology is on the top; for conditioned place preference tests, 
pregabalin was given 30 min after each morphine dose just before the 
conditioning sessions. (A) Representative traces of AMPAR- and NMDAR-
mediated currents (scale bar = 50 pA/ 50 ms, left) and the AMPA/NMDA 
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ratios in VTA DA neurons of midbrain slices obtained ex vivo 24 h after the 
drug injection in TH-EGFP mice. Morphine (1, 3 and 10 mg/kg, M1, M3 and 
M10; n = 7-10 mice) dose-dependently increased the AMPA/NMDA ratio 
(morphine effect: F3,30 = 8.9, p < 0.001, Bonferroni *** p < 0.01 as compared 
to vehicle). Pregabalin (50 mg/kg, P50) administered 30 min later (n = 6-10 
mice) enhanced morphine-induced neuroadaptations (pregabalin effect: F1,40 
= 8.9, p < 0.001, Bonferroni # p < 0.05, ## p < 0.01 as compared to 
corresponding morphine-alone group). (B, C) Conditioned place preference 
expressed as timeshifts between post- and pre-conditioning times spent in the 
drug-paired compartment of the apparatus at 96 h after the last conditioning 
session. (B) The timeshift of the group pretreated with morphine (1 mg/kg, 
M1-P50) was significantly different from the control (Veh+Sal) and pregabalin-
morphine groups (50 mg/kg-1 mg/kg; P50-M1) (treatment effect: F3,28 = 16.7, 
p < 0.01, Bonferroni * p < 0.05, *** p < 0.001 as compared to M1+P50). (C) 
The timeshift of the group pretreated with morphine (3 mg/kg, M3+P50) was 
significantly different only from the control (Veh+Sal) (treatment effect: F3,35 = 
8.5, p < 0.001, Bonferroni * p < 0.05 as compared to M3+P50). (D, E) 
Locomotor activity during the 30-min conditioning sessions after injections of 
the vehicle and drugs. Locomotor activity during the morning session was 
similar from day to day in all treatment groups and did not differ between the 
groups (Greenhose-Geisser test p ˃ 0.05 for the time x treatment interaction). 
(D) The M1+P50 group had the highest locomotor activity as compared with 
other treatment groups (treatment effect: F3,28 = 16.7, p < 0.01, Bonferroni * p 
< 0.05 as compared to Veh+Sal, and # p < 0.05 as compared to M1+P50). (E) 
The M3+P50 group had the highest locomotor activity as compared with other 
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treatment groups (treatment effect: F3,28 = 33.5, p < 0.001, Bonferroni * p < 
0.05 as compared to Veh+Sal, and # p < 0.05 as compared to M3+P50). Data 
are shown as means + SEMs. 
 
Figure 6. 
Effects of pregabalin and clonidine on opioid withdrawal in heroin abusers 
during the 6-day detoxification treatment. (A) The pregabalin group (n = 19) 
showed significantly higher retention levels as compared to the clonidine 
group (n = 15) (79% in pregabalin group vs. 47% in clonidine group, Fisher’s 
exact test, p = 0.05). (B) Pregabalin patients reported feeling better than 
clonidine patients on the overall health self-assessment scale. (C) The 
number of reported adverse effects in the pregabalin (left) and clonidine (right) 
groups. Pregabalin patients experienced significantly less low energy states, 
fatigue and tiredness than clonidine patients (# p < 0.05, Fisher’s exact test). 
(D) Intake of the NSAID ketorolac was significantly lower in the pregabalin 
group (* p < 0.05, t-test). Pregabalin patients demonstrated lower scores in 
opioid craving (E), depression (F), and anxiety (G) than clonidine patients. 
Withdrawal scores in subjective (H), objective (I) and clinical estimation (J) 
remained the same in the two treatment groups. Data are shown as means ± 
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